Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.
Highlights:
- Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
- Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
- Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
- Completion of usability study for submission for additional OTC clearance for the Pulse.
- Strong clinical sales pipeline with momentum towards new Q2 contracts.
- Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
- New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.
Click here for the September Quarterly Appendix 4C
Click here for the full ASX Release
This post appeared first on investingnews.com